Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Johnson Controls International PLC — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while Johnson Controls International PLC trades at $155.13 (market cap $94.45B). The key difference: Johnson Controls International PLC is far larger — about 20.1× Definium Therapeutics Inc. Common Shares's market cap, and Johnson Controls International PLC pays a 1.03% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Johnson Controls International PLC for 65 Days on average.
| DFTX | JCI | |
|---|---|---|
Market Cap | $4.71B | $94.45B |
Volume | 1,966,636 | 1,850,585 |
Sector | Health | Basic Materials |
52-Week High | $48.45 | $158.76 |
52-Week Low | $10.68 | $105.55 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $3.67B | $103.29B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JCI trades at $154.00, down 3.0% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported strong Q2 2026 earnings, beating estimates with $1.42 EPS, and raised full-year guidance. Revenue for 2025 was $23.60B, with net income surging to $3.29B, driving a net margin of 13.94%. Analysts maintain a bullish consensus with a $172.50 price target, and recent news highlights institutional accumulation and positive coverage in AI industrial stocks.
JCI presents a favorable investment case supported by earnings momentum, robust profitability, and analyst optimism, though valuation multiples are elevated. Key risks include high debt levels, competitive pressures, and sensitivity to economic cycles. The stock's proximity to resistance at $157 suggests near-term consolidation potential, but fundamental strength supports long-term upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
